权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Large-Scale Evaluation of the Effect of Rare Genetic Variants on Psychiatric Symptoms and Cognitive Ability

大规模评估罕见遗传变异对精神症状和认知能力的影响

基本信息

批准号：
9760145
负责人：
Laura A. Almasy
金额：
$ 104.61万
依托单位：
BOSTON CHILDREN'S HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-05-06 至 2024-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9760145
关键词：
Algorithms Boston Clinic Communities Complex Copy Number Polymorphism Data Set Developmental Disabilities Diagnosis Diagnostic Dimensions Evaluation Gene Mutation General Population Genes Genetic Genomics Glass Individual Knowledge Locales Location Maps Measurement Medical Genetics Mental Depression Mental disorders Modeling Moods Nature Neurocognitive Outcome Patient Self-Report Patients Pediatric Hospitals Phenotype Philadelphia Population Principal Investigator Psyche structure Psychopathology Psychotic Disorders Recurrence Regulatory Element Relative Risks Research Domain Criteria Research Personnel Resources Risk Sampling Schizophrenia Variant Work autism spectrum disorder base cognitive ability cognitive testing cohort cost effective data archive data sharing gene function genetic architecture genetic variant genome-wide insight instrument interest medical specialties multidisciplinary neurodevelopment neuropsychiatric disorder neuropsychiatry novel phenotypic data prevent psychiatric symptom rare genetic disorder repository symptomatology tool trait web-based tool

项目摘要

PROJECT SUMMARY/ABSTRACT Rare copy number variants (CNVs) are strongly associated with neuropsychiatric disorders, suggesting that they might serve as a magnifying glass to study general mechanisms of psychopathology as otherwise subtle perturbations to neuropsychiatric functions may be more clearly discerned through the major `hit' of the CNV. However, our understanding of the impact of CNVs on psychiatric symptomatology, RDoC domains and neurocognitive ability (termed `dimensional neuropsychiatric phenotypes') is limited in at least three ways. First, the effects sizes of the vast majority of CNVs on neuropsychiatric phenotypes remain poorly understood and their rarity will likely to prevent individual association studies. Prior studies concentrated on the most recurrent CNVs, leaving more than 90% of these variants undocumented. Second, for CNVs frequent enough to be studied individually, the full spectrum of phenotypic variation is unknown because ascertainment has been performed through neurodevelopmental and specialty clinics, which presumably represent the severe end of the phenotypic spectrum. Only a few studies have been conducted in unselected populations. Finally, many CNVs seem to impact the same neuropsychiatric domains, suggesting a poly/omnigenic model for psychiatric symptomatology, RDoC domains and neurocognitive ability. Based on this hypothesis, our previous work has shown that genetic scores and functional annotations can accurately predict the effect of any CNV on IQ but these approaches have not yet been extended beyond IQ to other dimensional neuropsychiatric phenotypes. We will fill these knowledge gaps with a novel, multidisciplinary, collaborative project that leverages existing archival data (n=255,303) to estimate and predict the effect sizes of CNVs (duplications and deletions) on dimensional neuropsychiatric phenotypes. Our aims include 1) phenotypic harmonization; 2) characterizing previously identified risk CNVs for mental illness in a large in general population cohorts and in samples ascertained for mental illnesses; 3) examine the contribution of common variants to variable expressivity of rare CNVs via polygenic risk scores (PRS) in the domains of mood, psychosis, developmental disability, and general cognitive ability; and 4) develop novel models to explain the effect size of any rare CNVs on dimensional neuropsychiatric phenotypes. Finally, we will develop tools for data sharing. Dr. David Glahn, Boston Children's Hospital, Dr. Laura Almasy, Children's Hospital of Philadelphia, and Dr. Sébastien Jacquemont, Centre Hospitalier Universitaire Sainte-Justine, are co-principal investigators on this application and bring complementary domains of expertise to the project. As this project involves analysis of existing archival data, it is an exceptionally cost-effective approach to better characterizing the rare genetic variants and elucidating general principles regarding the genetic architecture of dimensional neuropsychiatric phenotypes. Our application is responsive to RFA-MH-19-200.

项目概要/摘要罕见拷贝数变异（CNV）与神经精神疾病密切相关，这表明它们可以作为放大镜来研究精神病理学的一般机制，否则很微妙通过 CNV 的主要“打击”，可以更清楚地辨别对神经精神功能的干扰。然而，我们对 CNV 对精神症状学、RDoC 领域和神经认知能力（称为“维度神经精神表型”）至少在三个方面受到限制。第一的，绝大多数 CNV 对神经精神表型的影响大小仍然知之甚少，它们的稀有性可能会阻碍个体关联研究。之前的研究主要集中在最常见的 CNV，其中 90% 以上的变异没有记录在案。其次，对于 CNV 足够频繁的情况单独研究，表型变异的全部范围是未知的，因为确定已经通过神经发育和专科诊所进行，这大概代表了表型谱。仅在未选择的人群中进行了少数研究。最后，很多 CNV 似乎影响相同的神经精神领域，这表明精神病学存在多基因/全基因模型症状学、RDoC 领域和神经认知能力。基于这个假设，我们之前的工作表明遗传评分和功能注释可以准确预测任何 CNV 对 IQ 的影响，但这些方法尚未扩展到智商以外的其他维度的神经精神表型。我们将通过一个新颖的、多学科的协作项目来填补这些知识空白，该项目利用现有的档案数据 (n=255,303) 来估计和预测 CNV（重复和删除）对维度神经精神表型。我们的目标包括 1) 表型协调； 2）表征先前在大量普通人群和样本中发现了精神疾病的风险 CNV 确定患有精神疾病； 3）检查常见变体对变量表达性的贡献通过多基因风险评分 (PRS) 在情绪、精神病、发育障碍和一般认知能力； 4) 开发新模型来解释任何罕见 CNV 的影响大小维度神经精神表型。最后，我们将开发数据共享工具。波士顿儿童医院的 David Glahn 博士、费城儿童医院的 Laura Almasy 博士和圣贾斯汀大学中心医院的 Sébastien Jacquemont 是该项目的联合首席研究员应用程序并将互补的专业领域引入到项目中。由于该项目涉及分析现有的档案数据，这是一种极具成本效益的方法，可以更好地表征稀有遗传变异并阐明有关维度神经精神遗传结构的一般原则表型。我们的应用程序响应 RFA-MH-19-200。